PULMONARY HYPERTENSION (PH) -> PH - Pulmonary Arterial Hypertension Abstracts

1310 - Treatment of Drug- and Toxin-Induced Pulmonary Arterial Hypertension (PAH): Real-World Experience with Macitentan

Presentation Number
1310
Speakers
Session Name
POSTER SESSION 3 - POSTER SESSION: Pulmonary Hypertension and CTEPH
Date
Fri, Apr 24, 2020
Time
06:00 PM - 07:15 PM
Authors

Previous ePresentation
1308 - The Effect of Exercise on Endothelin 1 Level in Patients with Pulmonary Hypertension

Next ePresentations
1313 - Prognostic Significance of Echocardiographic Parameters in Predicting Early Decline in Patients with Pulmonary Arterial Hypertension
1314 - Adding Echocardiography of the Right Heart to Risk Assessment Scores in Prostanoid-Treated Pulmonary Arterial Hypertension
1325 - Cangrelor with Heparin for Patients with Heparin-Induced Thrombocytopenia Undergoing Pulmonary Thromboendarterectomy
1329 - Dobutamine-Induced Eosinophilic Myocarditis in Decompensated Heart Failure: A Paradoxical Dilemma
1331 - Myocardial Calcifications in an Orthotopic Heart Transplant as a Possible Cause of Primary Allograft Dysfunction
1332 - Severe Cardiac Allograft Vasculopathy: To Treat or Not to Treat Donor Specific Antibodies?
1333 - Recurrent Abdominal Pain in a Transplant Patient - A Diagnosis Not to Miss
1334 - High-Output Failure of a Transplanted Heart Due to Arteriovenous Fistula from Femoral Venous Access
1335 - Diagnosis of Malignant Hyperthermia is Confounded Immediately Post Heart Transplant
1336 - A Pentad to Rule Them All, a Story of the Perils of West Nile in a Heart Transplant Recipient